Effects of glucagon-like peptide-1(7–36)amide on motility and sensation of the proximal stomach in humans

Schirra, J, Wank, U, Arnold, R, Göke, B, Katschinski, M·2002·Gut
DOI 10.1136/gut.50.3.341

Cited by (129)

Items 101–129 of 129

  1. Incretins and Regulation of Insulin Secretion
    Michael Albrecht Nauck, Juris Jendrik Meier · 2008 · Springer eBooks
  2. Asprosin ve Glikoz Metabolizması Üzerine Etkileri
    M. Gizem KESER, Nurhan Ünüsan · 2021 · Turkish Journal of Diabetes and Obesity
  3. Vaciado gástrico y dispepsia funcional
    Sílvia Delgado-Aros · 2006 · Gastroenterología y Hepatología
  4. Acute glucagon-like peptide-1 receptor agonist, semaglutide, attenuates cue-, drug-, and stress-induced fentanyl seeking in male Sprague–Dawley rats
    Brianna Evans, Nikhil Acharya, Christopher G. Brandl, Elise Shealy, Jennifer E. Nyland, Christopher S. Freet, Scott C. Bunce, Patricia S. Grigson · 2026 · Behavioural Pharmacology
  5. Impact of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) on Increased Residual Gastric Content in Patients With and Without Concurrent Colonoscopy: A Retrospective Case–Control Study
    Shiyi Chang, Yan Tang, Meng Wang, Shengjun Zhu, Xi Tan, Xiaowei Fan, LY Lu, Bensong Duan, Li Shen · 2026 · Journal of Clinical Medicine
  6. Strategies to overcome hepatic clearance of endogenous proteins – molecular and formulation approaches
    Kirstin Meiners, Tobias Stepic, Lorenz Meinel, Tessa C. Lühmann · 2026 · RSC Chemical Biology
  7. Pancreatic polypeptide: A potential biomarker of glucose‐dependent insulinotropic polypeptide receptor activation in vivo
    Simon Veedfald, Natasha Chidekel Bergmann, Tina Vilsbøll, Mikkel Christensen, Jens Juul Holst, Filip Krag Knop · 2021 · Diabetic Medicine
  8. GIP und GLP-1-Rezeptoragonismus in der Therapie des Typ 2 Diabetes mit Fokus auf Tirzepatid
    Michael Albrecht Nauck, Matthias Blüher, Sebastian M. Meyhöfer, Elke Heitmann, Sven Wolfgang Görgens · 2023 · Diabetologie und Stoffwechsel
  9. Nutrition Strategies for Patients on New Incretin Therapies for Type 2 Diabetes
    Susan Keen, Kay Craven, Kathryn M. Kolasa · 2014 · Nutrition Today
  10. Food intake regulation: Relevance to bariatric and metabolic endoscopic therapies
    Daniel Gonzalez Izundegui, Sneha Singh, Andres J Acosta · 2020 · Techniques and Innovations in Gastrointestinal Endoscopy
  11. Gut hormones profile after an Ivor Lewis gastro-esophagectomy and its relationship to delayed gastric emptying
    Ji Chung Tham, Dimitri J. Pournaras, Bruno Alcocer, Rosie Forbes, Arun Ariyarathenam, Martyn Lee Humphreys, Richard G Berrisford, Tim Wheatley, David S. Y. Chan, Grant Sanders et al. · 2022 · Diseases of the Esophagus
  12. The efficacy and safety of vildagliptin in the GALIANT trial: chronic kidney disease and other applications
    Philip E. Otterbeck, Mary Ann Banerji · 2011 · Expert Review of Endocrinology & Metabolism
  13. Glucagon-Like Peptide 1 and Human Obesity
    Ananthi Anandhakrishnan, Márta Korbonits · 2017 · Elsevier eBooks
  14. Intestinal fat and eating behavior: role of the ileal brake
    Jeroen Maljaars · 2010
  15. Ingibitor dipeptidilpeptidazy-IV - sitagliptin: novye vozmozhnosti terapii sakharnogo diabeta 2 tipa
    Tatiana Ivanovna Romantsova · 2006 · Obesity and metabolism
  16. Regulation der gastroduodenalen Motilität und Perzeption durch endogenes Stickstoffmonoxid (NO) beim Menschen: Wirkungen und cholinerge Interaktion
    M Nicolaus · 2003
  17. Untersuchung der Effekte des GLP-1 Systems auf Komponenten des Metabolischen Syndrom in vivo
    Katja Piotrowski · 2013
  18. Bioinformatic studies of the disposition pathways and targets of synthetic drugs and herbal medicines
    Di, Yuan · 2012 · RMIT Research Repository (RMIT University Library)
  19. Factors involved in the regulation of gastrointestinal motility, hormone release, symptoms and energy intake in health and patients with functional dyspepsia.
    Amelia N. Pilichiewicz · 2008 · Adelaide Research & Scholarship (AR&S) (University of Adelaide)
  20. Glucose metabolism in the critically ill.
    AM Deane · 2012 · Adelaide Research & Scholarship (AR&S) (University of Adelaide)
  21. The Effect of Insulin and Insulin Resistance on Glucagon-like Peptide-1 Secretion from the Intestinal L Cell
    Gareth E. Lim · 2010 · TSpace (University of Toronto)
  22. Liraglutid in der Pharmakotherapie der Adipositas
    Swantje Brede, Hendrik Lehnert, Sebastian Michael Schmid · 2018 · Adipositas - Ursachen Folgeerkrankungen Therapie
  23. The Ozempic Generation: What the Interventional Radiologist Needs to Know About GLP ‐1 Agonists
    Suhail Wani, Salam Findakly, Tuan D. Phan, Matthew William Lukies, Gerard S. Goh, Georgina Venn, Tim Joseph, Jim Koukounaras, Warren Clements · 2025 · Journal of Medical Imaging and Radiation Oncology
  24. Case studies in disordered satiety and appetite
    2025 · Elsevier eBooks
  25. Comparison of sagittal and coronal views in point-of-care ultrasound assessment of gastric distention: A prospective cohort study
    Nicolette Meka, Kaitlin Krauss, Katie Rong, Timothy Herbst, Caroline Berberian, James Galske, Michael Kosover, Delaney Kehoe, Stephen G. Baker, Evan Masley et al. · 2025 · The American Journal of Emergency Medicine
  26. Impact of Obesity Medications on Gastric Function
    J. Alexander Torres, Shelby A. Sullivan · 2026 · Foregut The Journal of the American Foregut Society
  27. Molecular and cellular mechanisms of GLP-1 receptor agonists and their emerging clinical applications
    Mateusz Kurowski, Katarzyna Rekiel, Aleksandra Marcinkowska, Oskar Ratajczyk, Piotr Urbanowicz, Stanisław Iwankiewicz, Wojciech Grzelczak, Zuzanna Kaz mierczak · 2026 · Medical Journal of Cell Biology
  28. Tirzepatide for obesity without diabetes: mechanistic insights, clinical evidence, and future directions
    Wenting He, SONG Yi-di, Xinyu Wang, Si-Yuan He, Xue Tao, Shi-Xuan Yuan, Liang Zhou, En-Wu Long · 2026 · Frontiers in Pharmacology
  29. Pan-hypoileism: an endocrine disease
    Sérgio Santoro · 2026 · Einstein (São Paulo)